UPS
MCID: UND005
MIFTS: 66

Undifferentiated Pleomorphic Sarcoma (UPS)

Categories: Bone diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Undifferentiated Pleomorphic Sarcoma

MalaCards integrated aliases for Undifferentiated Pleomorphic Sarcoma:

Name: Undifferentiated Pleomorphic Sarcoma 53 59 6 17
Malignant Fibrous Histiocytoma 53 72
Ups 53 59
Malignant Fibrohistiocytic Tumors 53

Characteristics:

Orphanet epidemiological data:

59
undifferentiated pleomorphic sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (United States); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: any age;

Classifications:

Orphanet: 59  
Rare bone diseases


External Ids:

MESH via Orphanet 45 D051677
ICD10 via Orphanet 34 C49.9
UMLS via Orphanet 73 C0334463
Orphanet 59 ORPHA2023
UMLS 72 C0334463

Summaries for Undifferentiated Pleomorphic Sarcoma

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 2023DefinitionAn aggressive sarcoma of soft tissues or bone that can arise from any part of the body, clinically presenting as swelling, mass, pain, pathological fracture and occasional systemic features and is characterized by high local recurrence and significant metastasis.EpidemiologyUPS ranks the 4th most common soft tissue sarcoma with a slight male preponderance. The incidence has been evaluated to be close to 0.8-1 new case per 100000 per year in one European series.Clinical descriptionThe tumor arises most commonly during the sixth and seventh decades of life. The most common sites of involvement include lower extremities (mainly thigh) followed by upper arms, retroperitoneum, viscera, head and neck (in childhood). Primary osseous UPS most commonly occurs in distal femur, proximal tibia, proximal femur and humerus. Patients may present pain, swelling / mass and pathological fractures. In the skin, UPS presents as a relatively painless, rapidly enlarging nodule. Anorexia, malaise, fever and weight loss are present in retroperitoneal and inflammatory forms of UPS. Most UPS recur locally; distant metastases are common (the most frequent is lung). Regional metastases are rare.EtiologyUPS is thought to be derived from a primitive mesenchymal cell capable of differentiating into histiocytes, fibroblasts, myofibroblasts and osteoclasts. The etiology of the tumor remains unknown. Prior radiation therapy is a likely risk factor in some cases.Diagnostic methodsAny tumor mass over 5 cm is suspected to be a sarcoma. Magnetic resonance imaging (MRI) is the imaging method of choice for limbs and shows a high signal on T2 weighted images. Histology of biopsy specimen prior to any treatment is crucial to reach diagnosis and shows pleomorphic spindle cell population with large atypical cells frequently exhibiting numerous irregular mitotic figures, associated regions of hemorrhage and necrosis, associated lymphohistiocytic infiltrate and invasion of dermis. Immunohistochemical staining is negative for S-100, HMB-45, CD34 and cytokeratin which assists in ruling out other soft tissue tumors. Most cases previously diagnosed as malignant fibrous histiocytoma have been reclassified into other histological types of sarcoma.Differential diagnosisWhen occurring in skin, UPS is difficult to differentiate from atypical fibroxanthoma or dermatofibrosarcoma protuberans (see this term). Histological differential diagnoses include leiomyosarcoma, rhabdomyosarcoma, lymphoma, and melanoma (see these terms).Management and treatmentUPS should be referred to an expert/ reference center for primary biopsy, expert pathology review, and multidisciplinary treatment. Immediate surgery of a mass without knowledge of its histological nature is strongly discouraged because it is associated with an increased risk of death due to inappropriate resection and increased risk of relapse. UPS is best treated by wide surgical excision. Sometimes amputation may be necessary to remove the whole lesion. Adjuvant radiotherapy is given for high-grade, large (>5 cm), deep-seated tumors, in limb sparing surgeries and when negative margins are not obtained. For non-operable sarcomas, primary radiation therapy could be an option, but usually doxorubicin containing regimens are preferred options in first-line setting for locally irresectable and/or metastatic lesions. Chemotherapy (CHT) with ifosfamide, trabectedin, dacarbazine, pazopanib have demonstrated efficacy in UPS and are registered and available in most European Union countries.PrognosisA 5-year overall survival rate of 48% has been reported for patients with head and neck tumors versus 77% for patients with tumors arising on the trunk and extremities. The childhood variant appears have better prognosis.Visit the Orphanet disease page for more resources.

MalaCards based summary : Undifferentiated Pleomorphic Sarcoma, also known as malignant fibrous histiocytoma, is related to multiple enchondromatosis, maffucci type and oligodendroglioma. An important gene associated with Undifferentiated Pleomorphic Sarcoma is RECQL4 (RecQ Like Helicase 4), and among its related pathways/superpathways are HIV Life Cycle and TGF-Beta Pathway. The drugs Ifosfamide and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and breast, and related phenotypes are abnormality of the lower limb and abnormality of the peritoneum

Wikipedia : 75 Undifferentiated pleomorphic sarcoma, previously malignant fibrous histiocytoma, is a type of cancer,... more...

Related Diseases for Undifferentiated Pleomorphic Sarcoma

Diseases related to Undifferentiated Pleomorphic Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 5649)
# Related Disease Score Top Affiliating Genes
1 multiple enchondromatosis, maffucci type 32.0 IDH2 IDH1
2 oligodendroglioma 31.8 PDGFRA IDH2 IDH1
3 enchondroma 31.1 IDH2 IDH1
4 neurilemmoma 31.0 PDGFRA KIT EZR
5 differentiated thyroid carcinoma 30.8 NTRK1 MET KRAS
6 desmoid tumor 30.6 PDGFRA KIT
7 mixed glioma 30.6 PDGFRA IDH1
8 intrahepatic cholangiocarcinoma 30.5 KRAS IDH2 IDH1
9 carcinosarcoma 30.4 PIK3CA KRAS KIT
10 bladder urothelial carcinoma 30.0 PIK3CA KRAS KIT IDH1
11 intraductal papilloma 30.0 IDH2 IDH1
12 myeloma, multiple 29.9 STAT3 KRAS KIT IDH2 IDH1
13 cytogenetically normal acute myeloid leukemia 29.9 IDH2 IDH1
14 gastrointestinal system disease 29.8 STAT3 KRAS KIT
15 pulmonary vein stenosis 29.8 PDGFRA KIT
16 leukemia, acute myeloid 29.8 STAT3 KRAS KIT IDH2 IDH1
17 glioblastoma 29.7 PIK3CA PDGFRA MET IDH2 IDH1
18 glioma 29.7 PIK3CA PDGFRA MET IDH2 IDH1
19 adenoid cystic carcinoma 29.7 PIK3CA KRAS KIT IDH1
20 chondroblastic osteosarcoma 29.6 IDH2 IDH1 EZR
21 adenosquamous carcinoma 29.6 PIK3CA KRAS KIT
22 polycythemia vera 29.5 STAT3 PDGFRA KIT
23 myeloproliferative neoplasm 29.5 STAT3 PDGFRA KIT
24 intestinal disease 29.5 STAT3 PIK3CA KRAS
25 squamous cell carcinoma, head and neck 29.5 STAT3 PIK3CA MET IDH2
26 gastric leiomyosarcoma 29.5 PDGFRA KIT
27 hypereosinophilic syndrome, idiopathic 29.4 PDGFRA KIT
28 glioblastoma multiforme 29.4 STAT3 PIK3CA PDGFRA MET IDH1
29 lung cancer susceptibility 3 29.4 STAT3 PIK3CA MET KRAS IDH1
30 medulloblastoma 29.3 STAT3 PIK3CA PDGFRA NTRK1 IDH1
31 acral lentiginous melanoma 29.3 MET KIT
32 gastric adenocarcinoma 29.2 STAT3 PIK3CA MET KRAS KIT
33 spinal chordoma 29.2 PIK3CA PDGFRA MET
34 nervous system cancer 29.1 NTRK1 IDH2 IDH1
35 brain stem glioma 29.0 PIK3CA IDH2 IDH1
36 renal cell carcinoma, papillary, 1 28.9 PIK3CA MET KIT
37 respiratory system cancer 28.9 STAT3 PIK3CA MET KRAS
38 brain cancer 28.8 STAT3 PIK3CA PDGFRA IDH2 IDH1
39 central nervous system cancer 28.8 STAT3 IDH2 IDH1
40 pyosalpinx 28.7 PRDM10 KIT
41 large intestine cancer 28.6 STAT3 PIK3CA MET KRAS IDH2 IDH1
42 hepatocellular carcinoma 28.1 STAT3 PIK3CA MIR152 MET KRAS IDH2
43 cholangiocarcinoma 27.9 STAT3 PIK3CA MIR152 MET KRAS IDH2
44 gastrointestinal system cancer 27.9 STAT3 PIK3CA PDGFRA MET KRAS KIT
45 diaphyseal medullary stenosis with malignant fibrous histiocytoma 13.1
46 malignant fibrous histiocytoma of bone 12.8
47 ichthyosis tapered fingers midline groove up 12.3
48 kabuki syndrome 1 12.2
49 malignant fibroxanthoma 11.9
50 histiocytoma, angiomatoid fibrous 11.8

Graphical network of the top 20 diseases related to Undifferentiated Pleomorphic Sarcoma:



Diseases related to Undifferentiated Pleomorphic Sarcoma

Symptoms & Phenotypes for Undifferentiated Pleomorphic Sarcoma

Human phenotypes related to Undifferentiated Pleomorphic Sarcoma:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the lower limb 59 32 hallmark (90%) Very frequent (99-80%) HP:0002814
2 abnormality of the peritoneum 59 32 hallmark (90%) Very frequent (99-80%) HP:0002585
3 soft tissue sarcoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0030448
4 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
5 abnormality of the musculature 59 32 frequent (33%) Frequent (79-30%) HP:0003011
6 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
7 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
8 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
9 abnormality of the upper limb 59 32 occasional (7.5%) Occasional (29-5%) HP:0002817
10 abnormal test result 59 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.17 KIT MET
2 Decreased substrate adherent cell growth GR00193-A-2 9.17 KIT
3 Decreased substrate adherent cell growth GR00193-A-3 9.17 MET
4 Decreased substrate adherent cell growth GR00193-A-4 9.17 KIT MET NTRK1

MGI Mouse Phenotypes related to Undifferentiated Pleomorphic Sarcoma:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.38 AMPD2 CD74 EZR IDH1 KIT KRAS
2 immune system MP:0005387 10.32 AMPD2 CD74 EZR IDH1 KIT KRAS
3 mortality/aging MP:0010768 10.3 AMPD2 CD74 EZR IDH1 KIT KRAS
4 behavior/neurological MP:0005386 10.27 AMPD2 KIT KRAS LMNA MET NTRK1
5 hematopoietic system MP:0005397 10.22 CD74 EZR IDH1 KIT KRAS LMNA
6 digestive/alimentary MP:0005381 10.16 EZR KIT KRAS LMNA MET PDGFRA
7 endocrine/exocrine gland MP:0005379 10.15 KIT KRAS LMNA MET PDGFRA PIK3CA
8 integument MP:0010771 10.15 KIT KRAS LMNA MLANA NTRK1 PDGFRA
9 craniofacial MP:0005382 10.11 KIT KRAS LMNA MET PDGFRA RECQL4
10 muscle MP:0005369 10.03 KIT KRAS LMNA MET NTRK1 PDGFRA
11 limbs/digits/tail MP:0005371 10.02 KIT KRAS LMNA MET NTRK1 PDGFRA
12 neoplasm MP:0002006 10.01 IDH2 KIT KRAS MET PDGFRA PIK3CA
13 no phenotypic analysis MP:0003012 9.91 KIT KRAS MET MLANA NTRK1 PDGFRA
14 pigmentation MP:0001186 9.87 KIT KRAS LMNA MLANA NTRK1 PDGFRA
15 renal/urinary system MP:0005367 9.8 AMPD2 KIT KRAS LMNA MET PDGFRA
16 respiratory system MP:0005388 9.7 IDH1 KIT KRAS LMNA MET PDGFRA
17 skeleton MP:0005390 9.61 CD74 IDH1 KIT KRAS LMNA PDGFRA
18 vision/eye MP:0005391 9.23 KIT KRAS LMNA MET NTRK1 PIK3CA

Drugs & Therapeutics for Undifferentiated Pleomorphic Sarcoma

Drugs for Undifferentiated Pleomorphic Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3 3778-73-2 3690
2
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
3
Lenograstim Approved, Investigational Phase 3 135968-09-1
4
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
5
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
6
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
7
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
10
Epirubicin Approved Phase 3 56420-45-2 41867
11
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
12 Olaratumab Approved, Investigational Phase 3 1024603-93-7
13
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
14
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
15 Immunosuppressive Agents Phase 3
16 Immunologic Factors Phase 3
17 Anti-Infective Agents Phase 3
18 Antirheumatic Agents Phase 3
19 Antineoplastic Agents, Phytogenic Phase 3
20
Isophosphamide mustard Phase 3 0
21 Tubulin Modulators Phase 3
22 Antimitotic Agents Phase 3
23 Nucleic Acid Synthesis Inhibitors Phase 3
24 Etoposide phosphate Phase 3
25
Liposomal doxorubicin Phase 2, Phase 3 31703
26 Anti-Bacterial Agents Phase 2, Phase 3
27 Topoisomerase Inhibitors Phase 2, Phase 3
28 Antibiotics, Antitubercular Phase 2, Phase 3
29 Alkylating Agents Phase 2, Phase 3
30 Antineoplastic Agents, Alkylating Phase 2, Phase 3
31
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
32
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
33
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
34
Indinavir Approved Phase 2 150378-17-9 5362440
35
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
nivolumab Approved Phase 2 946414-94-4
38
Ipilimumab Approved Phase 2 477202-00-9
39
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 6436030 5284616 46835353
40
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
41
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
42
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
43
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
44
Pembrolizumab Approved Phase 2 1374853-91-4
45
Gemcitabine Approved Phase 2 95058-81-4 60750
46
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
47
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
48
Durvalumab Approved, Investigational Phase 2 1428935-60-7
49
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
50 Exatecan Investigational Phase 2 171335-80-1

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
2 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
4 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
5 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
8 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
9 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
11 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
12 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
13 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
15 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
16 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
17 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
18 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
19 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
20 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
21 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
22 Phase I/II Trial of Torisel and Liposomal Doxorubicin in Patients With Advanced Soft Tissue and Bone Sarcomas Completed NCT00949325 Phase 1, Phase 2 temsirolimus plus liposomal doxorubicin
23 Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients With Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
24 Phase II Study of Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF) Completed NCT00085475 Phase 2 imatinib mesylate
25 A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy Completed NCT00064220 Phase 2 soblidotin
26 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
27 Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment Completed NCT00041249 Phase 2 brostallicin
28 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
29 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
30 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
31 A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
32 SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity Recruiting NCT03092323 Phase 2 Pembrolizumab
33 Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2
34 A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Recruiting NCT03899805 Phase 2 Eribulin;Pembrolizumab
35 A Phase 1b Single Center Investigation of Safety/Efficacy of Nivolumab (Opdivo®) and ABI-009 (Nab-rapamycin) in Patients With Advanced Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Chondrosarcoma, Osteosarcoma and Ewing Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
36 A Phase I Study to Assess the Safety and Tolerability of Pembrolizumab in Combination With Fixed Rate Gemcitabine Chemotherapy in Patients With Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
37 A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma Recruiting NCT02923778 Phase 2
38 A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Recruiting NCT03474094 Phase 2
39 A Single-arm, Open, Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma Recruiting NCT04025931 Phase 2 chidamide and toripalimab
40 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting NCT02301039 Phase 2 Pembrolizumab
41 A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Active, not recruiting NCT02392637 Phase 2 Abraxane (Nab-Paclitaxel);Cisplatin;Gemcitabine
42 A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Active, not recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
43 A Single-arm, Single-center Prospective Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Patients Not yet recruiting NCT03946943 Phase 2 Anlotinib;Toripalimab
44 Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas Terminated NCT00740597 Phase 2
45 A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors Completed NCT02565758 Phase 1 ABBV-085
46 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
47 Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or Metastatic Soft Tissues Sarcomas Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
48 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
49 VORTEX-BIOBANK: Prospective Sample Collection for the VORTEX Randomised Radiotherapy Trial in Patients With Extremity Soft Tissue Sarcoma [VORTEX BIOBANK] Unknown status NCT00900211
50 Genetic Study of Patients and Families With Diaphyseal Medullary Stenosis With Malignant Fibrous Histiocytoma of the Bone Completed NCT00007046

Search NIH Clinical Center for Undifferentiated Pleomorphic Sarcoma

Genetic Tests for Undifferentiated Pleomorphic Sarcoma

Anatomical Context for Undifferentiated Pleomorphic Sarcoma

MalaCards organs/tissues related to Undifferentiated Pleomorphic Sarcoma:

41
Bone, Lung, Breast, Skin, Heart, Liver, Kidney

Publications for Undifferentiated Pleomorphic Sarcoma

Articles related to Undifferentiated Pleomorphic Sarcoma:

(show top 50) (show all 3964)
# Title Authors PMID Year
1
Neoadjuvant isolated limb perfusion in newly diagnosed untreated patients with locally advanced soft tissue sarcomas of the extremities: the Gustave Roussy experience. 38
30656606 2019
2
The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study. 38
31209624 2019
3
Paraneoplatic Obstruction of Descending Thoracic Aorta: A New Indication for Endovascular Surgery? 38
30610854 2019
4
An extremely rare primary sarcoma of the lung with peritoneal and small bowel metastases: a case report. 38
31426804 2019
5
Undifferentiated Pleomorphic Sarcoma With Emperipolesis. 38
31436108 2019
6
[A Case of Methadone Induced Drowsiness Following Trabectedin Induced Liver Injury]. 38
31296833 2019
7
Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors. 38
31257026 2019
8
Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. 38
31342400 2019
9
Undifferentiated pleomorphic sarcomas with PRDM10 fusions have a distinct gene expression profile. 38
31313299 2019
10
Differing characteristics of cartilaginous lesions of the larynx. 38
31338576 2019
11
TP53 in bone and soft tissue sarcomas. 38
31276706 2019
12
Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. 38
31350181 2019
13
Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts. 38
31331295 2019
14
Soft-tissue sarcoma in adolescents and young adults compared with older adults: A report among 5000 patients from the Scandinavian Sarcoma Group Central Register. 38
31287163 2019
15
Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases. 38
31364245 2019
16
Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Updates on Classification and Management. 38
31084719 2019
17
G-CSF-producing Undifferentiated Pleomorphic Sarcoma Adjacent to the Ascending Colon and in the Right Iliopsoas Muscle: A Case Report and Review of the Literature. 38
31243197 2019
18
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma. 38
31208434 2019
19
Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. 38
30962320 2019
20
A rare case of primary malignant fibrous histiocytoma: a sarcoma of the kidney. 38
31164132 2019
21
Combined treatment for a large primary cardiac sarcoma: a case report. 38
31209653 2019
22
Clinical Outcomes of Surgical Treatment for Primary Chest Wall Soft Tissue Sarcoma. 38
31236374 2019
23
Rapidly Progressive Malignant Fibrous Histiocytoma of Right Atrium: a Rare Case Report. 38
31310479 2019
24
Ischiorectal fossa: benign and malignant neoplasms of this "ignored" radiological anatomical space. 38
30955068 2019
25
Hypertensive Crisis during MW Ablation of Adrenal Neoplasms: A Retrospective Analysis of Predictive Factors. 38
31155498 2019
26
A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS). 38
31089155 2019
27
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. 38
31096717 2019
28
Multifocal pleomorphic dermal sarcoma and the role of inflammation and immunosuppression in a lung transplant patient: a case report. 38
31142349 2019
29
Multidisciplinary approach to rare primary cardiac sarcoma: a case report and review. 38
31151427 2019
30
Primary Undifferentiated Pleomorphic Sarcoma of the Colon Mesentery. 38
31142106 2019
31
Radiation-Associated Laryngeal Malignant Fibrous Histiocytoma. 38
31046455 2019
32
Malignant fibrous histiocytoma of the mandible - A case report and review of published case reports. 38
31211040 2019
33
Current situation of soft tissue sarcomas: Registry of a Latin American cancer institute. 38
30777256 2019
34
Dedifferentiated gastrointestinal stromal tumor: Recent advances. 38
30661742 2019
35
Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies. 38
30970016 2019
36
Apatinib regulates the cell proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling. 38
30686547 2019
37
A rare case of ovarian carcinosarcoma with squamous cell carcinoma. 38
30947745 2019
38
[Fillet flap used for reconstruction after hemipelvectomy and amputation of a lower extremity]. 38
30864542 2019
39
Periprosthetic femoral fractures around tumor endoprostheses treated with limited revision surgery combined with allograft: A case report. 38
30921224 2019
40
Atypical Fibroxanthoma. 38
31051027 2019
41
Malignant solitary fibrous tumor in the subcutis: Report of a rare superficial malignant type and review of published work. 38
30614065 2019
42
Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California. 38
30889920 2019
43
Large Undifferentiated Pleomorphic Sarcoma of the Posterior Thigh. 38
30853708 2019
44
The first ever reported case of malignant fibrous histiocytoma of the scalp. 38
30168269 2019
45
Long-Term Survival after Wide Resection of Malignant Fibrous Histiocytoma of the Chest Wall. 38
30834216 2019
46
[Bilateral back elastofibroma after resection of malignant fibrous histiocytoma of the right upper arm: a case report]. 38
30884936 2019
47
The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University. 38
30557163 2019
48
The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1. 38
30303565 2019
49
Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study. 38
30568874 2019
50
Differentiating intrapulmonary metastases from different primary tumors via quantitative dual-energy CT based iodine concentration and conventional CT attenuation. 38
30691666 2019

Variations for Undifferentiated Pleomorphic Sarcoma

ClinVar genetic disease variations for Undifferentiated Pleomorphic Sarcoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 RECQL4 NM_004260.3(RECQL4): c.1717C> T (p.Gln573Ter) single nucleotide variant Likely pathogenic 8:145739734-145739734 8:144514350-144514350

Cosmic variations for Undifferentiated Pleomorphic Sarcoma:

9 (show top 50) (show all 227)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM212945 XPO1 soft tissue,lower extremity,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 6
2 COSM44683 TP53 soft tissue,arm,leiomyosarcoma,NS c.652G>A p.V218M 17:7674879-7674879 6
3 COSM45253 TP53 soft tissue,arm,rhabdomyosarcoma,NS c.611A>G p.E204G 17:7674920-7674920 6
4 COSM10654 TP53 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.637C>T p.R213* 17:7674894-7674894 6
5 COSM44732 TP53 soft tissue,bone,leiomyosarcoma,NS c.512A>G p.E171G 17:7675100-7675100 6
6 COSM10648 TP53 soft tissue,NS,rhabdomyosarcoma,pleomorphic c.524G>A p.R175H 17:7675088-7675088 6
7 COSM43632 TP53 soft tissue,bone,leiomyosarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 6
8 COSM44151 TP53 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 6
9 COSM11476 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.452C>A p.P151H 17:7675160-7675160 6
10 COSM45256 TP53 soft tissue,arm,rhabdomyosarcoma,NS c.871A>C p.K291Q 17:7673749-7673749 6
11 COSM10660 TP53 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.818G>A p.R273H 17:7673802-7673802 6
12 COSM11073 TP53 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1024C>T p.R342* 17:7670685-7670685 6
13 COSM10672 TP53 soft tissue,retroperitoneum,leiomyosarcoma,NS c.577C>T p.H193Y 17:7674954-7674954 6
14 COSM10725 TP53 soft tissue,NS,rhabdomyosarcoma,pleomorphic c.701A>G p.Y234C 17:7674262-7674262 6
15 COSM43919 TP53 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.856G>T p.E286* 17:7673764-7673764 6
16 COSM6897049 TOP1 soft tissue,lower extremity,leiomyosarcoma,NS c.1576G>C p.E526Q 20:41114093-41114093 6
17 COSM6911821 SUFU soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.780G>T p.E260D 10:102597163-102597163 6
18 COSM6979022 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 6
19 COSM6945139 RICTOR soft tissue,NS,rhabdomyosarcoma,pleomorphic c.2898-1G>T p.? 5:38952426-38952426 6
20 COSM3399394 RB1 soft tissue,retroperitoneum,leiomyosarcoma,NS c.1004T>G p.L335* 13:48367558-48367558 6
21 COSM6964600 RB1 soft tissue,retroperitoneum,leiomyosarcoma,NS c.345C>G p.F115L 13:48342679-48342679 6
22 COSM389868 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 6
23 COSM5564171 PTPRT soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3424C>T p.R1142W 20:42106818-42106818 6
24 COSM6927085 PTPRT soft tissue,lower extremity,leiomyosarcoma,NS c.1201C>T p.R401W 20:42472515-42472515 6
25 COSM6933928 PTPRD soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.5686T>C p.S1896P 9:8317927-8317927 6
26 COSM6979014 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 6
27 COSM5923 PTEN soft tissue,retroperitoneum,leiomyosarcoma,NS c.1027-7T>C p.? 10:87965280-87965280 6
28 COSM5033 PTEN soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.389G>A p.R130Q 10:87933148-87933148 6
29 COSM5154 PTEN soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.697C>T p.R233* 10:87957915-87957915 6
30 COSM6959031 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 6
31 COSM1083818 PIK3CG soft tissue,NS,rhabdomyosarcoma,spindle cell c.2638G>A p.E880K 7:106883041-106883041 6
32 COSM1537052 PIK3CA soft tissue,retroperitoneum,leiomyosarcoma,NS c.1798G>A p.E600K 3:179219622-179219622 6
33 COSM6920563 PIK3CA soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.168C>A p.Y56* 3:179198993-179198993 6
34 COSM6979006 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 6
35 COSM6979021 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 6
36 COSM6955391 NTRK3 soft tissue,retroperitoneum,leiomyosarcoma,NS c.452G>A p.S151N 15:88147347-88147347 6
37 COSM6078150 NTRK3 soft tissue,retroperitoneum,leiomyosarcoma,NS c.1577C>A p.P526Q 15:88032865-88032865 6
38 COSM6964921 NTRK3 soft tissue,NS,rhabdomyosarcoma,spindle cell c.492C>A p.C164* 15:88137534-88137534 6
39 COSM584 NRAS soft tissue,retroperitoneum,rhabdomyosarcoma,NS c.182A>G p.Q61R 1:114713908-114713908 6
40 COSM575 NRAS soft tissue,skin,sarcoma,NS c.38G>C p.G13A 1:114716123-114716123 6
41 COSM580 NRAS soft tissue,retroperitoneum,rhabdomyosarcoma,NS c.181C>A p.Q61K 1:114713909-114713909 6
42 COSM6911819 NOTCH4 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2738C>G p.S913C 6:32210879-32210879 6
43 COSM48604 NOTCH3 soft tissue,lower extremity,leiomyosarcoma,NS c.2741C>T p.P914L 19:15181627-15181627 6
44 COSM6915774 NKX2-1 soft tissue,upper extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.314G>T p.R105M 14:36519044-36519044 6
45 COSM1745010 MYOD1 soft tissue,NS,rhabdomyosarcoma,spindle cell c.365T>G p.L122R 11:17720147-17720147 6
46 COSM6916495 MTOR soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.4799A>G p.E1600G 1:11144721-11144721 6
47 COSM293555 MSH6 soft tissue,lower extremity,leiomyosarcoma,NS c.3991C>T p.R1331* 2:47806641-47806641 6
48 COSM6919714 MPL soft tissue,lower extremity,leiomyosarcoma,NS c.1880T>C p.L627P 1:43352744-43352744 6
49 COSM6927083 MGA soft tissue,lower extremity,leiomyosarcoma,NS c.2057C>A p.S686Y 15:41698906-41698906 6
50 COSM6986229 MDM2 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.865G>A p.A289T 12:68836696-68836696 6

Expression for Undifferentiated Pleomorphic Sarcoma

Search GEO for disease gene expression data for Undifferentiated Pleomorphic Sarcoma.

Pathways for Undifferentiated Pleomorphic Sarcoma

Pathways related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 STAT3 PIK3CA PDGFRA MET LMNA KRAS
2
Show member pathways
13.47 STAT3 PIK3CA PDGFRA NTRK1 MET KRAS
3
Show member pathways
13.43 STAT3 PIK3CA PDGFRA MET KRAS KIT
4
Show member pathways
12.93 STAT3 PDGFRA NTRK1 MET KRAS KIT
5
Show member pathways
12.92 PDGFRA NTRK1 MET KIT EZR
6
Show member pathways
12.87 PIK3CA PDGFRA NTRK1 MET KRAS KIT
7
Show member pathways
12.81 STAT3 PIK3CA PDGFRA MET KRAS
8
Show member pathways
12.77 STAT3 PIK3CA PDGFRA NTRK1 KRAS
9
Show member pathways
12.72 STAT3 PIK3CA PDGFRA NTRK1 KRAS KIT
10 12.66 PDGFRA NTRK1 MET KRAS KIT
11 12.64 STAT3 PIK3CA PDGFRA NTRK1 MET KRAS
12
Show member pathways
12.62 PIK3CA PDGFRA MET KRAS KIT
13
Show member pathways
12.6 STAT3 PIK3CA PDGFRA MET KRAS
14
Show member pathways
12.6 STAT3 PIK3CA NTRK1 MET KRAS
15
Show member pathways
12.56 PIK3CA PDGFRA NTRK1 MET KRAS KIT
16 12.55 PIK3CA PDGFRA KRAS EZR
17
Show member pathways
12.51 STAT3 PIK3CA PDGFRA KRAS
18
Show member pathways
12.5 STAT3 PIK3CA MET KRAS
19 12.49 STAT3 MLANA KIT CD74
20
Show member pathways
12.42 PIK3CA PDGFRA MET KRAS
21
Show member pathways
12.37 STAT3 PIK3CA MET KRAS
22
Show member pathways
12.33 STAT3 PIK3CA PDGFRA KRAS
23
Show member pathways
12.31 PIK3CA PDGFRA KRAS KIT
24
Show member pathways
12.28 PIK3CA PDGFRA NTRK1 MET KRAS
25
Show member pathways
12.12 PDGFRA NTRK1 MET KRAS KIT
26 12.11 STAT3 PIK3CA MET KRAS EZR
27
Show member pathways
12.1 STAT3 PIK3CA PDGFRA NTRK1 MET KRAS
28
Show member pathways
12.02 STAT3 PIK3CA PDGFRA KRAS
29
Show member pathways
12.01 STAT3 PIK3CA MET KRAS
30 12 PDGFRA NTRK1 MET KIT
31 11.99 STAT3 PIK3CA PDGFRA MIR152 MET KRAS
32
Show member pathways
11.98 PIK3CA PDGFRA NTRK1 MET LMNA KRAS
33 11.84 STAT3 PIK3CA KRAS
34 11.8 STAT3 PIK3CA KRAS
35 11.79 PIK3CA PDGFRA NTRK1 MET LMNA KRAS
36
Show member pathways
11.77 STAT3 PIK3CA KRAS
37
Show member pathways
11.72 PIK3CA KRAS KIT
38 11.66 PDGFRA NTRK1 KRAS EZR
39
Show member pathways
11.55 STAT3 PIK3CA NTRK1
40
Show member pathways
11.35 STAT3 PIK3CA MET
41 11.26 STAT3 PIK3CA PDGFRA NTRK1 KRAS
42 11.01 PIK3CA PDGFRA NTRK1 MET KRAS KIT
43 10.93 PDGFRA NTRK1 MET KIT EZR
44
Show member pathways
10.77 IDH2 IDH1

GO Terms for Undifferentiated Pleomorphic Sarcoma

Cellular components related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 PDGFRA NTRK1 MET KIT CD74
2 receptor complex GO:0043235 8.92 PDGFRA NTRK1 MET KIT

Biological processes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.99 PIK3CA PDGFRA NTRK1 MET KIT
2 phosphorylation GO:0016310 9.93 STAT3 PIK3CA PDGFRA NTRK1 MET KIT
3 positive regulation of gene expression GO:0010628 9.92 STAT3 LMNA KRAS KIT EZR
4 cytokine-mediated signaling pathway GO:0019221 9.88 STAT3 PIK3CA KRAS KIT
5 positive regulation of cell proliferation GO:0008284 9.87 STAT3 PDGFRA KRAS KIT
6 MAPK cascade GO:0000165 9.84 PDGFRA MET KRAS KIT
7 peptidyl-tyrosine phosphorylation GO:0018108 9.8 PDGFRA NTRK1 MET KIT
8 positive regulation of protein kinase B signaling GO:0051897 9.78 PIK3CA PDGFRA MET KIT
9 liver development GO:0001889 9.73 PIK3CA MET KRAS
10 energy homeostasis GO:0097009 9.61 STAT3 PIK3CA AMPD2
11 2-oxoglutarate metabolic process GO:0006103 9.6 IDH2 IDH1
12 positive regulation of phospholipase C activity GO:0010863 9.58 PDGFRA KIT
13 negative regulation of apoptotic process GO:0043066 9.58 STAT3 NTRK1 CD74
14 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.56 PDGFRA NTRK1 MET KIT
15 NADP metabolic process GO:0006739 9.55 IDH2 IDH1
16 isocitrate metabolic process GO:0006102 9.51 IDH2 IDH1
17 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.46 PDGFRA NTRK1 KIT CD74
18 glyoxylate cycle GO:0006097 9.32 IDH2 IDH1
19 positive regulation of MAPK cascade GO:0043410 9.26 PDGFRA NTRK1 KIT CD74
20 phosphatidylinositol phosphorylation GO:0046854 9.07 PIK3CA
21 phosphatidylinositol-mediated signaling GO:0048015 8.92 PIK3CA PDGFRA NTRK1 EZR

Molecular functions related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.8 PIK3CA PDGFRA NTRK1 MET KIT
2 protein homodimerization activity GO:0042803 9.77 STAT3 PDGFRA NTRK1 KIT IDH1
3 protein tyrosine kinase activity GO:0004713 9.62 PDGFRA NTRK1 MET KIT
4 isocitrate dehydrogenase activity GO:0004448 9.26 IDH2 IDH1
5 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH2 IDH1
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 PDGFRA NTRK1 MET KIT
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.65 PIK3CA

Sources for Undifferentiated Pleomorphic Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....